Clinical and pathological features of screen vs non-screen-detected prostate cancers: Is there a difference?

BJU International

Volumn 102, Issue 1, 2008, Pages 24-27

  Pelzer, Alexandre E ^a,c   Colleselli, Daniela ^a   Bektic, Jasmin ^a   Schaefer, Georg ^a   Ongarello, Stefano ^b   Schwentner, Christian ^a   Pallwein, Leo ^a   Mitterberger, Michael ^a   Steiner, Eberhard ^a   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer; Prostate; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; DIAGNOSIS RELATED GROUP; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

AGED; AUSTRIA; COHORT STUDIES; EARLY DIAGNOSIS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROGRAM EVALUATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 44849126959     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07566.x     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003 53 : 5 26
3. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993 43 : 7 26
4. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002 60 : 756 9
5. Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int 2002 90 : 686 93
6. Horninger W, Berger A, Pelzer A et al. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol 2005 12 (Suppl. 1 7 13
7. Pelzer A, Bektic J, Berger AP et al. Prostate cancer detection in men with prostate specific antigen 4-10 ng/mL using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005 173 : 1926 9
8. Oesterling JE. Age-specific reference ranges for serum PSA. N Engl J Med 1996 335 : 345 6
9. Pelzer AE, Bektic J, Akkad T et al. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2-10 ng/mL. J Urol 2007 178 : 93 7
10. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 90
11. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998 159 : 1368 72
12. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 78
13. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 28 : 555 65
14. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
15. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002 168 : 525 9
16. Graif T, Loeb S, Roehl KA et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007 178 : 88 92
17. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 74
18. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000 21 : 251S 72S
19. de Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002 97 : 237 44
20. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004 172 : 129 32
21. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994 152 : 1714 20
22. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002 60 : 469 73